CSF3 and graft versus host disease: Clinical trials have shown that patients with a higher M1/M2 ratio have a higher risk of GVHD, and the use of granulocyte colony-stimulating factor (G-CSF) reduces the M1/M2 ratio and thus, significantly decreases the incidence of GVHD [236,256].